Announcement PDF Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia +61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 1 ASXAnnouncement Racura Oncology Adelaide Investor Briefing 4 September 2026 Racura Oncology Ltd (“Racura” or the “Company”) wishes to invite interested investors to attend an investor briefing in Adelaide (South Australia) on Wednesday, 30 September 2026. Managing Director and Chief Executive Officer, Dr Daniel Tillett, will host a morning tea, where investors will have the opportunity to hear the latest Company updates and ask questions about the Company’s clinical programs. Briefing Details Date Wednesday, 30 September 2026 Time 10:15AM for a 10:30AM start Location Adina Adelaide Treasury (Vault 2 room) 2 Flinders St, Adelaide, South Australia RSVP Places are limited so please RSVP before 21 September 2026 via: racura@irdepartment.com.au -ENDS- Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia +61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 2 About Racura Oncology Racura Oncology (ASX: RAC) is a Phase 3 clinical-stage biopharmaceutical company with a mission to silence cancer. Racura’s lead asset, (E,E)-bisantrene, is a clinically derisked small-molecule anticancer agent that primarily acts by stabilising G4-DNA and RNA structures, driving potent silencing of c-MYC, a key cancer gene dysregulated in up to 70% of all cancers. (E,E)-bisantrene has shown therapeutic activity in cancer patients and has a well-characterised safety profile. Racura’s discoveries have supported composition-of- matter IP filings that, if granted, could provide up to 20 years of patent protection for (E,E)-bisantrene. Racura is advancing RC220, its proprietary formulation of (E,E)-bisantrene, to address significant unmet need across multiple MYC-driven oncology indications. The Company’s clinical programs include the EMILI Phase 3 trial in acute myeloid leukaemia, the HARNESS Phase 1a/b trial in combination with osimertinib for EGFR-mutated non-small cell lung cancer, and the CPACS Phase 1a/b trial in combination with doxorubicin, where Racura aims to deliver both anthracycline cardioprotection and enhanced anticancer activity. Racura has collaborated with Astex, Emory University, Purdue University, MD Anderson Cancer Center, Sheba Medical Center, University of North Carolina School of Medicine, University of Wollongong, and the University of Newcastle. Racura is actively exploring partnerships, licence agreements, and potential commercial merger and acquisition opportunities to accelerate global patient access to RC220. Learn more at www.racuraoncology.com. For questions about this announcement or previous Racura Oncology announcements, please visit our Interactive Announcements page. Racura encourages our investors to go paperless by registering their email details with the Company’s share registry, Automic Registry Services, at www.automicgroup.com.au. Release authorised by Media Contact Daniel Tillett, CEO/MD Cherie Hartley +61 418 737 020 info@racuraoncology.com cherie.hartley@irdepartment.com.au